ARTICLE | Clinical News
Nusinersen: Interim Phase III data
August 8, 2016 7:00 AM UTC
The 13-month, double-blind, international Phase III ENDEAR trial in 122 patients with infantile-onset SMA was stopped early after a pre-specified interim analysis showed that intrathecal nusinersen fo...